FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis

被引：131

作者：

Gan, Boyi ^{[1
,2
,3
,4
]}

Lim, Carol ^{[1
,2
,3
,4
]}

Chu, Gerald ^{[1
,3
,4
,5
]}

Hua, Sujun ^{[1
,2
,3
,4
]}

Ding, Zhihu ^{[1
,2
,3
,4
]}

Collins, Michael ^{[5
]}

Hu, Jian ^{[1
,2
,3
,4
]}

Jiang, Shan ^{[1
,2
,3
,4
]}

Fletcher-Sananikone, Eliot ^{[1
,2
,3
,4
]}

Zhuang, Li ^{[1
,2
,3
,4
]}

Chang, Michelle ^{[5
]}

Zheng, Hongwu ^{[1
,2
,3
,4
]}

Wang, Y. Alan ^{[1
,2
,3
,4
]}

Kwiatkowski, David J. ^{[6
]}

Kaelin, William G., Jr. ^{[2
,3
,7
]}

Signoretti, Sabina ^{[2
,5
]}

DePinho, Ronald A. ^{[1
,2
,3
,4
]}

机构：

[1] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA

[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA

[6] Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA

[7] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA

来源：

CANCER CELL | 2010年 / 18卷 / 05期

关键词：

C-MYC; CELL CARCINOMA; MTOR PATHWAY; HISTONE DEACETYLASE; N-COR; COMPLEX; METABOLISM; REPRESSION; INDUCTION; CANCER;

D O I：

10.1016/j.ccr.2010.10.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

mTORC1 is a validated therapeutic target for renal cell carcinoma (RCC). Here, analysis of Tsc1-deficient (mTORC1 hyperactivation) mice uncovered a FoxO-dependent negative feedback circuit constraining mTORC1-mediated renal tumorigenesis. We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and Fox Os; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes. Mechanistically, integrated analyses revealed that FoxO-mediated block operates via suppression of Myc through upregulation of the Myc antagonists, Mxi1-SR alpha and mir-145, establishing a FoxO-Mxi1-SR alpha/mir-145 axis as a major progression block in renal tumor development.

引用

页码：472 / 484

页数：13

共 54 条

[31] 2004 WHO classification of the renal tumors of the adults
Lopez-Beltran, A
Scarpelli, M
Rodolfo, M
Kirkali, Z
[J]. EUROPEAN UROLOGY, 2006, 49 (05) : 798 - 805
[32] Targeting the PI3K-Akt pathway in human cancer: Rationale and promise
Luo, J
Manning, BD
Cantley, LC
[J]. CANCER CELL, 2003, 4 (04) : 257 - 262
[33] Molecular mechanisms of mTOR-mediated translational control
Ma, Xiaoju Max
Blenis, John
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2009, 10 (05) : 307 - 318
[34] Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, DJ
Rowan, A
Lavoie, T
Natarajan, L
Kelly, BD
Ye, SQ
Garcia, JGN
Semenza, GL
[J]. BLOOD, 2005, 105 (02) : 659 - 669
[35] Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis
Manning, BD
[J]. JOURNAL OF CELL BIOLOGY, 2004, 167 (03) : 399 - 403
[36] AKT/PKB signaling: Navigating downstream
Manning, Brendan D.
Cantley, Lewis C.
[J]. CELL, 2007, 129 (07) : 1261 - 1274
[37] Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Motzer, Robert J.
Escudier, Bernard
Oudard, Stephane
Hutson, Thomas E.
Porta, Camillo
Bracarda, Sergio
Gruenwald, Viktor
Thompson, John A.
Figlin, Robert A.
Hollaender, Norbert
Urbanowitz, Gladys
Berg, William J.
Kay, Andrea
Lebwohl, David
Ravaud, Alain
[J]. LANCET, 2008, 372 (9637) : 449 - 456
[38] FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis
Paik, Ji-Hye
Kollipara, Ramya
Chu, Gerald
Ji, Hongkai
Xiao, Yonghong
Ding, Zhihu
Miao, Lili
Tothova, Zuzana
Horner, James W.
Carrasco, Daniel R.
Jiang, Shan
Gilliland, D. Gary
Chin, Lynda
Wong, Wing H.
Castrillon, Diego H.
DePinho, Ronald A.
[J]. CELL, 2007, 128 (02) : 309 - 323
[39] Prognostic relevance of the mTOR pathway in renal cell carcinoma - Implications for molecular patient selection for targeted therapy
Pantuck, Allan J.
Seligson, David B.
Klatte, Tobias
Yu, Hong
Leppert, John T.
Moore, Laurence
O'Toole, Timothy
Gibbons, Jay
Belldegrun, Arie S.
Figlin, Robert A.
[J]. CANCER, 2007, 109 (11) : 2257 - 2267
[40] Renal cell carcinoma
Rini, Brian I.
Campbell, Steven C.
Escudier, Bernard
[J]. LANCET, 2009, 373 (9669) : 1119 - 1132

← 1 2 3 4 5 6 →